查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1458449

糖尿病黃斑部水腫市場規模：按治療類型、應用和最終用戶分類 - 區域前景、競爭策略和細分市場預測（截至 2033 年）

Diabetic Macular Edema Market Size- By Treatment Type, By Application, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 235 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計2033年，全球糖尿病黃斑部水腫市場規模將成長至152.5億美元，年複合成長率為4.69%。

糖尿病性視力喪失的主要原因之一是糖尿病性黃斑部水腫（DME）。 DME 被認為是由視網膜脈管系統滲透性引起的。黃斑部水腫的嚴重程度與糖尿病視網膜病變有關。糖尿病黃斑部水腫的病理和發展背後的分子機制很複雜，需要更深入地了解這種疾病的分子途徑和病理。

本報告調查了全球糖尿病黃斑部水腫市場，並提供了市場概況、市場影響因素和市場機會分析、市場規模趨勢和預測、各個細分市場和地區的詳細分析、競爭格局以及主要企業。的。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第4章市場動態

  • 促進因素、限制因素、機會與挑戰分析
  • COVID-19 對市場的影響

第5章 市場變數與展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 熱圖分析

第6章 競爭狀況

  • 製造地、銷售區域、產品類型分佈
  • 併購、聯盟、產品發布、合作

第7章全球糖尿病黃斑部水腫市場：依治療類型

  • 全球市佔率及預測
  • 藥物治療
  • 雷射治療

第8章全球糖尿病黃斑部水腫市場：依應用分類

  • 全球市佔率及預測
  • 黃斑部水腫
  • 黃斑部病變

第9章全球糖尿病黃斑部水腫市場：依最終用戶分類

  • 全球市佔率及預測
  • 醫院
  • 診所
  • 其他

第10章全球糖尿病黃斑部水腫市場預測

  • 市場規模/市場佔有率

第11章全球糖尿病黃斑部水腫市場：依治療類型

  • 市場規模/市場佔有率趨勢/預測

第12章全球糖尿病黃斑部水腫市場：依應用分類

  • 市場規模/市場佔有率趨勢/預測

第 13 章全球糖尿病黃斑部水腫市場：依最終用戶分類

  • 市場規模/市場佔有率趨勢/預測

第14章全球糖尿病黃斑部水腫市場：按地區

  • 市場規模/市場佔有率趨勢/預測
  • 亞太地區
  • 歐洲
  • 中東/非洲
  • 北美洲
  • 拉丁美洲

第15章 公司簡介

  • Alimera Sciences Inc.
  • Abbvie Inc.
  • Bayer AG
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Kubota Pharmaceutical Hodlings Co. Ltd.
  • Novartis AG
  • Regen X Bio Inc.
  • Regeneron Pharmaceuticals Inc.
  • 其他

第16章簡稱

第17章 參考鏈接

第18章結論

第19章 研究範圍

簡介目錄
Product Code: PHAR2403

Diabetic Macular Edema Market Introduction and Overview

According to SPER market research, 'Diabetic Macular Edema Market Size- By Treatment Type, By Application, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Diabetic Macular Edema Market is predicted to reach USD 15.25 billion by 2033 with a CAGR of 4.69%.

One of the most frequent reasons of diabetic vision loss is diabetes-related macular edema (DME). It is believed to be brought on by the hyper permeability of the retinal vasculature. Macular edema and the severity of diabetic retinopathy are related. Due to the complexity of the pathophysiology and molecular mechanisms behind the development of diabetic macular edema, a deeper understanding of the disease's molecular pathways and pathogenesis is required.

The COVID-19 virus first surfaced in December 2019 and has since spread to nearly every country in the world, prompting the World Health Organisation (WHO) to declare a public health emergency. The global healthcare system has been badly disrupted in the aftermath of the coronavirus pandemic due to the financial crisis and the delay in delivering specialist healthcare while prioritising COVID-19 treatments.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Treatment Type, By Application, By End User

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Abbvie Inc., Alimera Sciences Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Kubota Pharmaceutical,Hodlings Co. Ltd., Novartis AG, Regen X Bio Inc., Regeneron Pharmaceuticals Inc.,

Global Diabetic Macular Edema Market Segmentation:

By Treatment Type: Based on the Treatment Type, Global Diabetic Macular Edema Market is segmented as; Drug Therapy and Laser Treatment.

By Application: Based on the Application, Global Diabetic Macular Edema Market is segmented as; Macular Edema and Macular Degeneration.

By End User: Based on the End User, Global Diabetic Macular Edema Market is segmented as; Hospital, Clinics and Other.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impacts of the Global Diabetic Macular Edema Market

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Diabetic Macular Edema Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Diabetic Macular Edema Market

7. Global Diabetic Macular Edema Market, By Treatment Type (USD Million)

  • 7.1. Global Diabetic Macular Edema Market Value Share and Forecast, By Treatment Type, 2024-2033
  • 7.2. Drug Therapy
  • 7.3. Laser Treatment

8. Global Diabetic Macular Edema Market, By Application (USD Million)

  • 8.1. Global Diabetic Macular Edema Market Value Share and Forecast, By Application, 2024-2033
  • 8.2. Macular Edema
  • 8.3. Macular Degeneration

9. Global Diabetic Macular Edema Market, By End User (USD Million)

  • 9.1. Global Diabetic Macular Edema Market Value Share and Forecast, By End User, 2024-2033
  • 9.2. Hospital
  • 9.3. Clinics
  • 9.4. Others

10. Global Diabetic Macular Edema Market Forecast, 2020-2033 (USD Million)

  • 10.1. Global Diabetic Macular Edema Market Size and Market Share

11. Global Diabetic Macular Edema Market, By Treatment Type 2020-2033 (USD Million)

  • 11.1. Global Diabetic Macular Edema Market Size and Market Share By Treatment Type (2020-2026)
  • 11.2. Global Diabetic Macular Edema Market Size and Market Share By Treatment Type (2027-2033)

12. Global Diabetic Macular Edema Market, By Application, 2020-2033 (USD Million)

  • 12.1. Global Diabetic Macular Edema Market Size and Market Share By Application (2020-2026)
  • 12.2. Global Diabetic Macular Edema Market Size and Market Share By Application (2027-2033)

13. Global Diabetic Macular Edema Market, By End User, 2019-2033 (USD Million)

  • 13.1. Global Diabetic Macular Edema Market Size and Market Share By End User (2020-2026)
  • 13.2. Global Diabetic Macular Edema Market Size and Market Share By End User (2027-2033)

14. Global Diabetic Macular Edema Market, By Region, 2019-2033 (USD Million)

  • 14.1. Global Diabetic Macular Edema Market Size and Market Share By Region (2020-2026)
  • 14.2. Global Diabetic Macular Edema Market Size and Market Share By Region (2027-2033)
  • 14.3. Asia-Pacific
    • 14.3.1. Australia
    • 14.3.2. China
    • 14.3.3. India
    • 14.3.4. Japan
    • 14.3.5. South Korea
    • 14.3.6. Rest of Asia-Pacific
  • 14.4. Europe
    • 14.4.1. France
    • 14.4.2. Germany
    • 14.4.3. Italy
    • 14.4.4. Spain
    • 14.4.5. United Kingdom
    • 14.4.6. Rest of Europe
  • 14.5. Middle East and Africa
    • 14.5.1. Kingdom of Saudi Arabia
    • 14.5.2. United Arab Emirates
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. North America
    • 14.6.1. Canada
    • 14.6.2. Mexico
    • 14.6.3. United States
  • 14.7. Latin America
    • 14.7.1. Argentina
    • 14.7.2. Brazil
    • 14.7.3. Rest of Latin America

15. Company Profile

  • 15.1. Alimera Sciences Inc.
    • 15.1.1. Company details
    • 15.1.2. Financial outlook
    • 15.1.3. Product summary
    • 15.1.4. Recent developments
  • 15.2. Abbvie Inc.
    • 15.2.1. Company details
    • 15.2.2. Financial outlook
    • 15.2.3. Product summary
    • 15.2.4. Recent developments
  • 15.3. Bayer AG
    • 15.3.1. Company details
    • 15.3.2. Financial outlook
    • 15.3.3. Product summary
    • 15.3.4. Recent developments
  • 15.4. Bausch Health Companies Inc.
    • 15.4.1. Company details
    • 15.4.2. Financial outlook
    • 15.4.3. Product summary
    • 15.4.4. Recent developments
  • 15.5. F. Hoffmann-La Roche Ltd
    • 15.5.1. Company details
    • 15.5.2. Financial outlook
    • 15.5.3. Product summary
    • 15.5.4. Recent developments
  • 15.6. GlaxoSmithKline Plc
    • 15.6.1. Company details
    • 15.6.2. Financial outlook
    • 15.6.3. Product summary
    • 15.6.4. Recent developments
  • 15.7. Kubota Pharmaceutical Hodlings Co. Ltd.
    • 15.7.1. Company details
    • 15.7.2. Financial outlook
    • 15.7.3. Product summary
    • 15.7.4. Recent developments
  • 15.8. Novartis AG
    • 15.8.1. Company details
    • 15.8.2. Financial outlook
    • 15.8.3. Product summary
    • 15.8.4. Recent developments
  • 15.9. Regen X Bio Inc.
    • 15.9.1. Company details
    • 15.9.2. Financial outlook
    • 15.9.3. Product summary
    • 15.9.4. Recent developments
  • 15.10. Regeneron Pharmaceuticals Inc.
    • 15.10.1. Company details
    • 15.10.2. Financial outlook
    • 15.10.3. Product summary
    • 15.10.4. Recent developments
  • 15.11. Others

16. List of Abbreviations

17. Reference Links

18. Conclusion

19. Research Scope